FDA approves vaccines for RSV protection in infants and adults.
TL;DR Summary
Pfizer and Moderna are developing new versions of their Covid vaccines that aim to provide broader and longer-lasting immunity against the virus, and combination jabs that protect against Covid and other respiratory diseases in a single dose. Both companies aim to keep up with a shift in the US toward annual Covid shots rather than frequent booster doses. Pfizer and BioNTech are developing a vaccine that targets both Covid and the flu, while Moderna is developing a triple combination shot, which would target Covid, the flu, and RSV all at once.
- Here’s what Pfizer and Moderna say is next for their Covid vaccines CNBC
- FDA Advisors Recommend Approval for First Vaccine to Protect Babies From RSV NBC 5 Dallas-Fort Worth
- The Rising Threat of Salmonella, Anticipated FDA Approvals, and More: The Week's Top 5 Stories Contagionlive.com
- FDA's vote in favor of maternal RSV vaccine Good Morning America
- FDA Panel Votes to approve RSV for Infants PEOPLE
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
7 min
vs 8 min read
Condensed
94%
1,582 → 91 words
Want the full story? Read the original article
Read on CNBC